Indo Us Biotech financials

·FMCG & RetailChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹33.0cr+7.2% on Q1 FY26
Net profit
₹3.0cr−35.4% on Q1 FY26
EBITDA margin
12.0%−5.8 pts on Q1 FY26
EPS
₹1.51−35.7% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue33.030.8+7.2%
EBITDA4.05.5−27.6%
EBITDA margin12.0%17.8%−5.8 pts
Profit before tax3.14.8−36.2%
Net profit3.04.7−35.4%
EPS₹1.51₹2.35−35.7%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹33.0 crNet profit₹3.0 crNet margin9.2%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
157——
6.16.10.2
37.037.014.8
188——
113110104
—+6.4%—
15.517.018.9
13.8%15.4%18.2%
14.516.117.8
11.513.116.3
10.2%11.9%15.7%
₹5.71₹6.54₹8.11
—−19.3%—
—−16.1−1.4
—−2.40.0
−18.5−18.5−1.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹157 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——157.1
- Cash, Equiv & ST Investments0.26.16.1
+ Total Debt14.837.037.0
Enterprise Value——188.0
Revenue103.8110.4112.7
Growth %, YoY—+6.4—
EBITDA18.917.015.5
Margin %18.2315.4013.76
EBIT17.816.114.5
Net Income16.313.111.5
Margin %15.6711.8810.17
EPS, Adj (current shares)8.116.545.71
Growth %, YoY—-19.3—
Cash from Operations-1.4-16.1—
Capital Expenditures-0.0-2.4—
Free Cash Flow-1.4-18.5-18.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Indo Us Biotech financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Indo Us Biotech (NSE: INDOUS) had a market capitalisation of ₹157 crore at the previous close (₹78.36 a share), a PE ratio of 13.7 on the last four quarters' profit and a price-to-book ratio of 1.70. In FY26 its consolidated net profit was ₹13.1 crore on revenue of ₹110 crore; in Q1 FY27 (April–June 2026) it was ₹3 crore, down 35.4% year on year. Its debt-to-equity ratio was 0.40 on 31 March 2026. Promoters held 68.29% of the shares on 30 September 2026.

Share price used
₹78.36 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Indo Us Biotech at a glance · consolidated

Market cap
₹157 Crat ₹78.36 · previous close
PE ratio (last 4 quarters)
13.712.0 on FY26 profit
Price to book (PB)
1.70book value ₹46.15 a share
ROE (FY26)
15.3%ROCE 18.4%
Debt to equity
0.40net debt ₹30.9 Cr
Promoter holding
68.29%unchanged vs 30 Jun 202630 September 2026
Net worth
₹92.5 Cr+17.8% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹18.5 Cr
EPS (FY26)
₹6.54

Questions

What is the Indo Us Biotech PE ratio today?

Indo Us Biotech's PE ratio is 13.7 at the previous close (₹78.36 a share): a market capitalisation of ₹157 crore divided by consolidated net profit of ₹11.5 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹13.1 crore) it is 12.0.

What is the Indo Us Biotech debt to equity ratio?

Indo Us Biotech's debt-to-equity ratio was 0.40 on 31 March 2026: borrowings of ₹37 crore against total equity of ₹92.5 crore. A year earlier, on 31 March 2025, it was 0.19.

What is the Indo Us Biotech net worth?

Indo Us Biotech's net worth — shareholders' equity in its consolidated balance sheet — was ₹92.5 crore on 31 March 2026, up 17.8% from ₹78.5 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹157 crore at the previous close.

What is the Indo Us Biotech PB ratio (price to book value)?

Indo Us Biotech's price-to-book (PB) ratio is 1.70 at the previous close: a market capitalisation of ₹157 crore divided by shareholders' equity (book value) of ₹92.5 crore on 31 March 2026. That is a book value of ₹46.15 per share against a share price of ₹78.36.

What is the Indo Us Biotech ROE and ROCE?

In FY26, Indo Us Biotech's return on equity (ROE) was 15.3% and its return on capital employed (ROCE) was 18.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the Indo Us Biotech book value per share?

Indo Us Biotech's book value per share was ₹46.15 on 31 March 2026: shareholders' equity of ₹92.5 crore divided by the 2.01 crore shares in issue, up 17.8% from ₹39.16 a year earlier. The share price at the previous close was ₹78.36.

What is the Indo Us Biotech market cap?

Indo Us Biotech's market capitalisation was ₹157 crore at the previous close: 2.01 crore shares at ₹78.36 each.

What is the Indo Us Biotech EPS?

Indo Us Biotech's basic earnings per share (EPS) were ₹6.54 in FY26, against ₹8.12 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹5.70.

When are the Indo Us Biotech next results?

Indo Us Biotech will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, the date of the board meeting it has notified to the exchanges.

Is Indo Us Biotech debt free?

No. Indo Us Biotech had borrowings of ₹37 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.40. Its cash and current investments were ₹6.1 crore, so its net debt was ₹30.9 crore.

What is the Indo Us Biotech promoter holding?

Promoters held 68.29% of Indo Us Biotech on 30 September 2026, unchanged from the previous quarter and down 1.88 percentage points from 70.17% a year earlier, according to the shareholding pattern filed with NSE.

What is the Indo Us Biotech shareholding pattern?

On 30 September 2026, Indo Us Biotech's shares were held by promoters 68.29%, foreign portfolio investors (FII/FPI) 0.01%, domestic institutions (DII) 0.25% and retail and other non-institutional investors 31.45%.

What is the Indo Us Biotech free cash flow?

In FY26, Indo Us Biotech generated ₹16.1 crore of cash from operations and spent ₹2.4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹18.5 crore. In FY25 it was −₹1.4 crore.

What is the Indo Us Biotech revenue and profit in FY26?

In FY26 (April 2025–March 2026), Indo Us Biotech's consolidated net profit was ₹13.1 crore, down 19.3% from ₹16.3 crore in FY25, on revenue from operations of ₹110 crore (up 6.4%).

How does Indo Us Biotech compare with its peers?

On FY26 consolidated figures, against Kohinoor Foods and Nath Bio-Genes: Indo Us Biotech's operating margin of 14.6% is the highest of the three (Kohinoor Foods −8.1%, Nath Bio-Genes 10.9%; peer average 1.4%).

What are the Indo Us Biotech latest quarterly results?

Indo Us Biotech's latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit ₹3 crore, down 35.4% from ₹4.7 crore in Q1 FY26; revenue from operations ₹33 crore, up 7.2% year on year.

Indo Us Biotech vs Kohinoor Foods: how do they compare?

In FY26, Indo Us Biotech earned net profit of ₹13.1 crore on revenue of ₹110 crore, against ₹80.7 crore on ₹148 crore for Kohinoor Foods. Indo Us Biotech's operating margin was 14.6% (Kohinoor Foods −8.1%).

Where do these Indo Us Biotech figures come from?

From Indo Us Biotech's own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.